Tamtuvetmab

Tamtuvetmab (AT-005) is a caninised blontuvetmab against CD52. Tamtuvetmab increases progression-free survival (PFS), exhibits in vivo efficacy in dogs with naïve T-cell lymphoma (LSA). Tamtuvetmab has been approved by veterinary[1][2].

Research Areas >> Cancer

Signaling Pathways >> Others >> Others

CD52[1]

Tamtuvetmab (5 mg/mL, 7.5-30 mL; i.v.; 15-30 min) has in vivo efficacy in dogs with naïve T-cell lymphoma (LSA), but resulting in vomiting, weight loss, diarrhoea, lethargy, decreased appetite and anorexia[1]. Animal Model: T-cell LSA Model in Dog[1] Dosage: 5 mg/mL, 7.5-30 mL; Dogs weighing for 2-15 kg received 7.5 mL, for 15.1-30 kg received 15 mL, for 30.1-45 kg received 22.5 mL, for 45.1-60 kg received 30 mL Administration: Intravenous injection; 15-30 min Result: Showed in vivo efficacy with severe side effect.

[1]. Musser ML, et al. Randomised trial evaluating chemotherapy alone or chemotherapy and a novel monoclonal antibody for canine T-cell lymphoma: A multicentre US study. Vet Rec Open. 2022 Nov 1;9(1):e49.  

[2]. Rhodes L. Changing innovation into a registered product: From concept to regulatory approval. Theriogenology. 2018 May;112:75-81.